PMID- 22538170 OWN - NLM STAT- MEDLINE DCOM- 20120716 LR - 20151119 IS - 1096-0333 (Electronic) IS - 0041-008X (Linking) VI - 261 IP - 3 DP - 2012 Jun 15 TI - Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. PG - 280-91 LID - 10.1016/j.taap.2012.04.010 [doi] AB - Dasatinib, a multitargeted inhibitor of BCR-ABL and SRC kinases, exhibits antitumor activity and extends the survival of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). However, some patients suffer from hepatotoxicity, which occurs through an unknown mechanism. In the present study, we found that Dasatinib could induce hepatotoxicity both in vitro and in vivo. Dasatinib reduced the cell viability of rat primary hepatocytes, induced the release of alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) in vitro, and triggered the ballooning degeneration of hepatocytes in Sprague-Dawley rats in vivo. Apoptotic markers (chromatin condensation, cleaved caspase-3 and cleaved PARP) were detected to indicate that the injury induced by Dasatinib in hepatocytes in vitro was mediated by apoptosis. This result was further validated in vivo using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays. Here we found that Dasatinib dramatically increased the level of reactive oxygen species (ROS) in hepatocytes, reduced the intracellular glutathione (GSH) content, attenuated the activity of superoxide dismutase (SOD), generated malondialdehyde (MDA), a product of lipid peroxidation, decreased the mitochondrial membrane potential, and activated nuclear factor erythroid 2-related factor 2 (Nrf2) and mitogen-activated protein kinases (MAPK) related to oxidative stress and survival. These results confirm that oxidative stress plays a pivotal role in Dasatinib-mediated hepatotoxicity. N-acetylcysteine (NAC), a typical antioxidant, can scavenge free radicals, attenuate oxidative stress, and protect hepatocytes against Dasatinib-induced injury. Thus, relieving oxidative stress is a viable strategy for reducing Dasatinib-induced hepatotoxicity. CI - Crown Copyright (c) 2012. Published by Elsevier Inc. All rights reserved. FAU - Xue, Tao AU - Xue T AD - Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. FAU - Luo, Peihua AU - Luo P FAU - Zhu, Hong AU - Zhu H FAU - Zhao, Yuqin AU - Zhao Y FAU - Wu, Honghai AU - Wu H FAU - Gai, Renhua AU - Gai R FAU - Wu, Youping AU - Wu Y FAU - Yang, Bo AU - Yang B FAU - Yang, Xiaochun AU - Yang X FAU - He, Qiaojun AU - He Q LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120417 PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Antioxidants) RN - 0 (Fluorescent Dyes) RN - 0 (Indoles) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Pyrimidines) RN - 0 (Reactive Oxygen Species) RN - 0 (Thiazoles) RN - 47165-04-8 (DAPI) RN - 9007-49-2 (DNA) RN - EC 1.1.1.27 (L-Lactate Dehydrogenase) RN - EC 2.6.1.2 (Alanine Transaminase) RN - RBZ1571X5H (Dasatinib) RN - WYQ7N0BPYC (Acetylcysteine) SB - IM MH - Acetylcysteine/pharmacology MH - Alanine Transaminase/blood MH - Animals MH - Antioxidants/pharmacology MH - Apoptosis/*drug effects MH - Blotting, Western MH - Cell Separation MH - DNA/chemistry MH - Dasatinib MH - Electrophoresis, Gel, Pulsed-Field MH - Fluorescent Dyes MH - Hepatocytes/*drug effects MH - In Situ Nick-End Labeling MH - Indoles MH - L-Lactate Dehydrogenase/blood MH - Male MH - Membrane Potential, Mitochondrial/drug effects MH - Mitochondria, Liver/drug effects MH - Mitochondrial Swelling/drug effects MH - Oxidative Stress/*drug effects MH - Protein Kinase Inhibitors/*toxicity MH - Pyrimidines/*toxicity MH - Rats MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/metabolism MH - Thiazoles/*toxicity EDAT- 2012/04/28 06:00 MHDA- 2012/07/17 06:00 CRDT- 2012/04/28 06:00 PHST- 2011/11/15 00:00 [received] PHST- 2012/04/06 00:00 [revised] PHST- 2012/04/07 00:00 [accepted] PHST- 2012/04/28 06:00 [entrez] PHST- 2012/04/28 06:00 [pubmed] PHST- 2012/07/17 06:00 [medline] AID - S0041-008X(12)00146-9 [pii] AID - 10.1016/j.taap.2012.04.010 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2012 Jun 15;261(3):280-91. doi: 10.1016/j.taap.2012.04.010. Epub 2012 Apr 17.